Back to Results

Gigi Hirsch, MD

Training + Education University of Cincinnati; Residency: Brown University College of Medicine (Internal Medicine); Harvard Medical School (Psychiatry)
Board Certifications Psychiatry
Gender Female
Accepted Insurances View Accepted Insurances at Tufts Medical Center

Tufts Medical Center
35 Kneeland St., Floor 11
Boston, MA 02111
Phone #: 617-636-5065

Peer Recognition Award, Harvard Community Health Plan

Eichler, H.-G., Trusheim, M., Schwarzer-Daum, B., Larholt, K., … Hirsch, G. (2021). Precision Reimbursement for Precision Medicine: Using Real-World Evidence to Evolve From Trial-and-Project to Track-and-Pay to Learn-and-Predict. Clinical Pharmacology and Therapeutics, 111(1), 52-62.

Eichler, H.-G., Oye, K., Baird, L. G., Abadie, E., Brown, J., Drum, C. L., … Hirsch, G. (2012). Adaptive licensing: taking the next step in the evolution of drug approval. Clinical Pharmacology and Therapeutics, 91(3), 426–437.

Eichler, H.-G., Baird, L., Barker, R., Bloechl-Daum, B., Børlum-Kristensen, F., Brown, J., … Hirsch, G. (2015). From adaptive licensing to adaptive pathways: Delivering a flexible life-span approach to bring new drugs to patients. Clinical Pharmacology & Therapeutics, 97(3), 234–246.

Papadaki, M., & Hirsch, G. (2013). Curing Consortium Fatigue. Science Translational Medicine, 5(200), 200fs35-200fs35.

Hirsch, G. (2019). Leaping Together Toward Sustainable, Patient‐Centered Innovation: The Value of a Multistakeholder Safe Haven for Accelerating System Change. Clinical Pharmacology & Therapeutics, 105(4), 798–801.

Gigi Hirsch, MD is the Director for the Tufts Center for Biomedical System Design and its flagship program NEWDIGS (New Drug Development Paradigms) at the Institute for Clinical Research and Health Policy Studies and Assistant Professor at Tuft University School of Medicine. Prior to her arrival at Tufts Medical Center, Dr. Hirsch was the Executive Director of the MIT Center for Biomedical Innovation (2007-2022) where she founded and led NEWDIGS. Her prior experiences in clinical care and the biopharmaceutical industry led to her vision for NEWDIGS, a multi-stakeholder “think and do tank” that re-engineers connections between the upstream (research and development) and downstream (access to/use of drug therapies) systems to make both more patient-centered and sustainable. Under Dr. Hirsch’s leadership, NEWDIGS has advanced innovations in adaptive licensing of new drug therapies, outcomes-based payments models for durable cell and gene therapies, and real-world learning health systems designed to advance precision medicine. Her work in regulatory innovation led to her appointment on the Expert Advisory Committee of the President’s Council of Advisors on Science and Technology (PCAST) for a special report commissioned by President Obama on “Propelling Innovation in Drug Discovery, Development, and Evaluation” (2011-2012). Dr. Hirsch trained in Internal Medicine (Brown University College of Medicine) and Psychiatry (Harvard Medical School), and practiced Emergency Medicine (Brigham and Women’s Hospital and Harvard Community Health Plan) before transitioning to her role in commercial strategy at Millennium Pharmaceuticals. In addition, leveraging insights from her non-traditional career path in medicine, she was founder and CEO of a boutique entrepreneurial venture (MD IntelliNet), funded by Boston’s Beth Israel Hospital, where she coached physicians from pre-med through retirement on career management in the rapidly changing healthcare industry.